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Summary Background: Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the pa tients eventually developing metastases. Neuroendo crine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies. Case Report: A patient with liver metasta ses from BC was treated with peptide receptor radio nuclide therapy (PRRT). Computed tomography scan and biochemical examinations showed a clear response to radionuclide therapy. Conclusion: PRRT may be useful in metastatic BC patients.
Introduction
Breast cancer (BC) with neuroendocrine differentiation (NED) is a rare neoplasm. Tables 1 and 2 show, respectively, the most important locations of neuroendocrine tumors and their World Health Organization (WHO) classification. Many studies have reported overexpression of somatostatin receptors (SSTR) in primary BC both in vitro and in vivo [1] [2] [3] [4] [5] [6] [7] [8] , whereas fewer analyses have evaluated their pattern in BC. Many authors do not consider evidence of SSTR overexpression alone to be sufficient to define an NED and stress the importance of neuroendocrine markers such as chromogranin and synaptophysin. The prognostic factors resulting from NED in BC are still a matter of debate with some researchers suggesting that BC with NED is a unique clinicopathologic entity with a poor outcome [9, 10] , whereas others maintain a more open approach [11] .
Case Report
In Systemic Radionuclide Therapy in Breast Cancer 409 node dissection. Pathology showed ductal infiltrating carcinoma with NED, positive for estrogen and negative for progesterone and c-ERB receptors. 1 cycle of adjuvant external beam radiation therapy was carried out, followed by tamoxifen which was substituted with anastrozole and triptorelin for intolerance. This schedule was considered to perform a complete estrogen blockade in this perimenopausal patient and prevent a potentially detrimental effect of anastrozole on residual ovarian function (despite amenorrhea).
In June 2006, a computed tomography (CT) scan showed evidence of 3 liver metastases which were confirmed to be derived from BC by biopsy. Immunohistochemistry showed synaptophysin and chromogranin, strengthening the diagnosis of NED. Chemotherapy with docetaxel and epirubicin was carried out and achieved a radiological partial remission. In July 2007, a CT scan showed progression in the liver, and a second line of chemotherapy (vinorelbine and capecitabine) was scheduled leading to an apparent stabilization. However, CA15.3, chromogranine A (CgA), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) levels rose to 82 ng/ml (normal range < 34 ng/ml), 75 ng/ml (19-98 ng/ml), 20.6 ng/ml (< 18 ng/ml), and 32 ng/ml (< 4 ng/ml), respectively.
The lack of response to this second-line chemotherapy made it unlikely that a benefit be derived from other protocols, and therefore it was decided to focus on the striking NED. The overexpression of SSTR in the metastases was 'in vivo' detected by 111 In-pentetreotide scintigraphy. Both the scintigraphy and a whole body CT scan did not detect any additional locations. Tumor markers were as mentioned above (CA15.3 = 82 ng/ml, CgA = 75 ng/ml, NSE = 20.6 ng/ml, CEA = 32 ng/ml). fig. 2) .
Since the recruitment of this patient was unusual to our protocol, which is aimed to treat well-differentiated SSTR-positive GEP-NETs and not simply SSTR-positive cancers, we decided to obtain proof of efficacy of the therapy. For this purpose an abdominal CT scan was performed 1 month after the first treatment, which showed shrinkage of the metastasis located in the 6th liver segment ( fig. 3 ) and a lowering of the vital components of the metastasis in the 3rd segment. A nearly 50% reduction in CA15.3 (from 82 to 47.2 ng/ml), CgA (from 75 to 44 ng/ml), and CEA (from 32 to 23.6 ng/ml) was recorded. The impressive response encouraged us to progress with the treatment for a further 3 bimonthly cycles, as was scheduled for the GEP-NETs trial. A CT scan 1 month after the 2nd cycle showed a further reduction in the lesions located in the 6th and 8th liver segment and the disappearance of another metastasis previously detected in the 3rd segment ( fig. 4) . Indeed, CA15.3 levels continued to decrease from 45 to 32 to 26.1 and eventually to 22 ng/ml. The same trend was noted for CEA and CgA. A CT scan carried out 1 month after the end of the complete line of PRRT showed persistence of 1 liver metastasis only, reduced in diameter from 33 to 13 mm ( fig. 5 ). Biochemical marker levels measured at that time were CA15.3 20 ng/ml and normalized CEA and CgA. In order to gain the best therapeutic effect, it was proposed to the patient to reach the maximum tolerated dose (nearly 15 GBq) by adding 2 more cycles. However, she refused due to depression and self-reported claustrophobia. The patient was therefore 
Discussion
Little is known about NED in BC, including its impact on prognosis and the possibility to take advantage of SSTR. SSTR overexpression in BC could make PRRT worthwhile, and to our knowledge this is the first report to describe a biochemical complete response together with shrinkage of the neoplastic masses after treatment with 90 Y-DOTATOC. Despite this being a report of a single case, we believe that certain suggestions may be derived from it. As already reported in the literature for other cancers [12] [13] [14] [15] [16] , PRRT may be effective in neoplasms other than neuroendocrine tumors. Hopefully, and if confirmed in a large cohort of patients, this could determine an added value of PRRT in BC treatment. Moreover, in the era of treatments aimed at tumor stabilization, PRRT may provide objective and potentially striking tumor shrinkage even in aggressive disease. Finally, we suggest that PRRT may advance from being a second-or third-line therapy to a first-or second-line therapy within an intigrated schedule including all other therapeutic modalities for the treatment of both GEP-NETs and other SSTR-expressing neoplasms such as those described in this paper.
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Online Supplemental Figures   Fig. 1 . Pre-therapeutic CT scan showing 1 of 3 liver lesions. 
